Analysts’ Perspective: ViaSat (VSAT), SAGE Therapeutics (SAGE), James Hardie (JHX)

ViaSat Inc. (NASDAQ:VSAT) shares were upgraded by analysts at Needham from Hold to Buy rating with a price target of $78.

ViaSat, Inc. engages in the provision of fixed and mobile broadband services, advanced satellite and wireless networks and secure networking systems products and services.


Brokerage Firm Chardan Capital Markets upgraded Sage Therapeutics Inc. (NASDAQ:SAGE) shares from Neutral to Buy rating while increasing their price target from $60 to $140.

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company.


Investment Analysts at Citigroup upgraded James Hardie Industries Plc (NYSE:JHX) shares from Neutral to Buy rating.

James Hardie Industries Plc engages in the manufacturing of fiber cement products and systems for internal and external building construction applications.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at